Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEN-003 + Matrix M-2
- Development stage
- Phase 2
- Lead developer
- Genocea Biosciences, Inc.
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
GEN-003 + Matrix M-2 is a therapeutic vaccine candidate developed for the treatment of genital herpes simplex virus type 2 (HSV-2) infection. The vaccine consists of two recombinant HSV antigens—a transmembrane deletion mutant of glycoprotein D (gD2ΔTMR) and a large fragment of infected cell protein 4 (ICP4.2)—combined with the saponin-derived adjuvant Matrix-M2. GEN-003 is designed to elicit both humoral and cellular immune responses against HSV-2, reducing viral shedding and lesion rates in infected individuals. The addition of the Matrix-M2 adjuvant significantly enhances immunogenicity by stimulating robust antibody and T-cell responses[1][4][5]. Clinical trials have demonstrated that this combination can reduce HSV-2 shedding and lesion rates for at least six months post-treatment[1][4].
- Other names
- MM2MM-2MM 2Matrix-M2Matrix-M-2Matrix-M 2
02
Targets
gD (HSV-2 glycoprotein D)ICP4 (Infected cell protein 4)
Beyond the preview
Go deeper on GEN-003 + Matrix M-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEN-003 + Matrix M-2.